Literature DB >> 6575974

High-performance liquid chromatographic method for pharmacokinetic studies on the new anthracycline 4-demethoxydaunorubicin and its 13-dihydro derivative.

E Moro, V Bellotti, M G Jannuzzo, S Stegnjaich, G Valzelli.   

Abstract

The anthracyclines are a group of antitumoral antibiotics with significant clinical efficacy. Among the new anthracycline derivatives, 4-demethoxydaunorubicin showed interesting biological properties in terms of both spectrum of activity and therapeutic index and was recently introduced in clinical trials. The present paper describes the analytical method developed to investigate the pharmacokinetics of this derivative. The method consists of the extraction of 4-demethoxydaunorubicin and its 13-dihydro metabolite from plasma with chloroform--1-heptanol (9:1) and re-extraction with 0.3 M phosphoric acid, separation by high-performance liquid chromatography and quantification by sensitive fluorescence detection. Plasma level curves obtained from cancer patients treated with the drug are shown.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6575974     DOI: 10.1016/s0378-4347(00)84431-x

Source DB:  PubMed          Journal:  J Chromatogr


  9 in total

Review 1.  Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  L M Hollingshead; D Faulds
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

2.  High-performance liquid chromatographic analysis of idarubicin and fluorescent metabolites in biological fluids.

Authors:  C M Camaggi; P Carisi; E Strocchi; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients.

Authors:  L Zanette; M Zucchetti; A Freshi; D Erranti; U Tirelli; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia.

Authors:  T Fukushima; T Yamashita; N Goto; T Ueda; K I Okabe; Y Kuraishi; R Ohno; A Urabe; M Ogawa
Journal:  Int J Hematol       Date:  2001-10       Impact factor: 2.490

5.  Method for the determination of 4-demethoxydaunorubicin, its quinone and hydroquinone metabolites in human plasma and urine by high-performance liquid chromatography.

Authors:  J Cummings; R Milroy; S W Banham; S B Kaye
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 6.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

7.  Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients.

Authors:  O Y Hu; S P Chang; J M Jame; K Y Chen
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses.

Authors:  S Kaplan; C Sessa; Y Willems; M A Pacciarini; V Tamassia; F Cavalli
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

9.  Bioavailability and pharmacology of oral idarubicin.

Authors:  D J Stewart; D Grewaal; R M Green; S Verma; J A Maroun; D Redmond; L Robillard; S Gupta
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.